The size of the global mycoplasma testing market is estimated to worth USD 665.76 Million in 2022. This figure is forecasted to be growing at a CAGR of 12.7% to reach USD 1210.43 Million by 2027.
Mycoplasma contamination of cell culture has been a growing concern for most researchers for decades. Mycoplasma infection mainly originates from laboratory workers, as contamination with human mycoplasmas occurs at a faster rate.
MARKET DRIVERS:
Mycoplasma testing is carried out to combat further contamination, which is expected to increase the demand for related products and, hence, the global mycoplasma testing market.
The demand for mycoplasma test products is expected to increase in the near future with growing investment in R & D in life sciences. Tremendous opportunities in the life sciences segment are driving the growth of the market. Increased investment in the biotechnology and pharmaceutical industries and increased healthcare spending is expected to further fuel growth.
The increased research activities of pharmaceutical and biotechnology companies are reflected in adopting new technologies for drug discovery and development. In 2019, Boehringer Ingelheim announced plans to invest approximately USD 261 million for its new Biological Development Center (BDC), which will be located at its R&D site in Germany. Merck also plans to invest $ 18 billion in R&D over the next five years, in addition to its annual investment of $ 7.2 billion. Therefore, it is expected that a significant amount of R&D expenditure will drive developments in this area, thereby stimulating the demand for mycoplasma testing products.
Government initiatives in the form of awareness campaigns on chronic diseases, such as cancer, also promote research-based activities that are expected to boost the global mycoplasma testing market.
The National Research Council's Industrial Research and Assistance Program (NRC-IRAP) provides technological support to small and medium-sized life science companies in Canada involved in product development and innovation. According to Saudi Arabia's Vision 2040, its government promotes the growth of pharmaceutical industries as only 35% of its drug needs are produced locally.
The increasing introduction of new technologies by key players is expected to further fuel the mycoplasma testing market growth.
Another factor that stimulates growth is increased contamination of cell cultures. Due to the limitation of culture methods, researchers are involved in identifying and developing faster and more accurate mycoplasma tests in recent years. These rapid tests' main advantages would be high sensitivity, the ability to identify a wide range of mycoplasma species, and reduced cycle time, thus reducing production time. Nucleic Acid-Based Technology (NAT), which allows rapid detection of mycoplasmas in cell culture, is an example of an alternative method for culture-based assays. In 2019, the American Type Culture Collection announced its new polymerase chain reaction (PCR) -based service that helps detect contaminants in mycoplasma cell cultures.
Multiple government authorities progressively support research activities in the pharmaceutical and biotechnology departments. For example, the U.S. government provides financial support to global pharmaceutical companies to facilitate research activities to develop new drugs. In April 2020, the United States Food and Drug Administration (FDA) announced plans to change the regulations for the only test method used to detect mycoplasmas. According to the agency, the regulations are restrictive and avoid using other testing methods that could potentially detect mycoplasmas accurately. These changes in biologics regulation are expected to improve mycoplasma testing's sensitivity and specificity by developing new technologies. Therefore, an increase in government funding for pharmaceutical and biotechnology research has stimulated R & D activities, promoting mycoplasma test products' wide application.
MARKET RESTRAINTS:
The success of mycoplasma testing depends primarily on the analysts' experience and the environmental conditions under which the test is performed. Mycoplasma testing should be performed for optimum effectiveness by trained professionals with sufficient knowledge of this area's nuances. The handling of instruments used in mycoplasma tests also requires experience. Hence, the shortage of sufficiently skilled human resources poses a significant challenge to the growth of the mycoplasma testing market.
Impact of COVID-19 on the global mycoplasma testing market:
The sudden eruption of coronavirus (COVID 19) caused by the SARS-CoV-2 reagent affected many industries, particularly healthcare. The pandemic crisis has induced the medical sector to find a remedy for the dangerous infectious disease. The pandemic is to have an unbiased impact on the mycoplasma testing market growth during 2020 and 2021. Some of the COVID 19 patients may respond to antibiotics and anti-malaria treatment positively. They could be the outcome of inhibition of Mycoplasma species and other bacterial infections in groups of patients. And may be helpful to use molecular tests to examine the appearance of mycoplasma species and other pathogenic bacteria that are frequently found in ordinary pneumonia among all the hospitalized COVID 19 patients. When obtained positive outcomes, patients need to be treated accordingly to develop responses clinically and patient results.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2027 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2027 |
|
Segments Covered |
By Product, Technique, Application, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This market research report on the global mycoplasma testing market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2027.
Mycoplasma Testing Market – By Product:
Based on the product type, the Kits & Reagents segment is likely to have the largest share during the period.
Mycoplasma Testing Market – By Technique:
Based on the Technique type, the Polymerase Chain Reaction (PCR) segment is expected to hold the highest share market and high CAGR value. It is attributed to the large receiving rate of PCR due to the exact, speedy, and ease of modification. This PCR technique is used extensively for detecting mycoplasma as this is very quick, cheap, and not influenced by cell culture conditions.
Mycoplasma Testing Market – By Application:
Based on the Application type, the cell line testing segment is expected to have a high CAGR value during the period. The growth of this Application type is based on the factor like the growth rate of increasing pharmaceutical industries and clone that is derived from an individual antibody.
Mycoplasma Testing Market – By End User:
Based on the End-user, Pharmaceutical Companies share the highest market value attributed to the new innovative activities in the pharmaceutical and biotechnology companies.
Mycoplasma Testing Market – By Region:
Geographically, North America dominates the global mycoplasma testing market, and Europe is not far behind.
In 2020, North America dominated the mycoplasma testing market due to increased healthcare spending and investment by the US government to promote biopharmaceutical industries' research activities. Biopharmaceutical production in North America is also growing, requiring highly purified cultures to produce therapeutic products. According to the National Science Foundation, in 2020, the R & D sector in the United States experienced significant growth, which is expected to influence regional development positively.
Asia-Pacific region is projected to have the fastest growth rate due to the enormous opportunities available in countries like China, India, and Japan. Asia-Pacific is anticipated to grow at a lucrative growth rate during the forecast period. It is due to the significant awareness and fundraising initiatives generated by countries like India. The Indian government is carrying out several strategic initiatives to facilitate additional R & D activities to introduce new drugs. Also, healthcare organizations' regulatory policies that promote improved quality of biosafety are expected to increase growth opportunities shortly. For example, China has several regulatory bodies, such as the Ministry of Health, which oversee the approval of experiments and laboratories and oversight of biosafety. Increasing pharma and biotech companies and their investments in R&D and various government initiatives are expected to drive market growth.
KEY MARKET PARTICIPANTS:
Some of the noteworthy companies dominating the global mycoplasma testing market profiled in the report are Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Lonza Group Ltd., Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, PromoCell GmbH, WuXi AppTec.
RECENT HAPPENINGS IN THE MARKET:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Kits & Reagent
5.1.2.1 PCR Assays
5.1.2.2 Nucleic Acid Detection Kits
5.1.2.3 Elimination Kits & Reagents
5.1.2.4 Stains
5.1.2.5 Standards & Controls
5.1.2.6 Other Kits & Reagents
5.1.3 Instruments
5.1.4 Services
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Technique
5.2.1 Introduction
5.2.2 PCR
5.2.3 ELSA
5.2.4 Direct Assays
5.2.5 Indirect Assays
5.2.6 Microbial culture techniques
5.2.7 Enzymatic Methods
5.2.8 DNA Staining
5.2.9 Y-o-Y Growth Analysis, By Technique
5.2.10 Market Attractiveness Analysis, By Technique
5.2.11 Market Share Analysis, By Technique
5.3 Application
5.3.1 Introduction
5.3.2 Cell Line Testing
5.3.3 Virus Testing
5.3.4 End-Of-Production Cell Testing
5.3.5 Other Applications
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End-User
5.4.1 Introduction
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations
5.4.4 Academic Research Institutes
5.4.5 Cell Banks
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Technique
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Technique
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Technique
6.1.5.4 By Application
6.1.5.5 By End User
6.2 North America
6.2.1 Introduction
6.2.2 United States
6.2.3 Canada
6.3 Europe
6.3.1 Introduction
6.3.2 U.K
6.3.3 Spain
6.3.4 Germany
6.3.5 Italy
6.3.6 France
6.4 Asia-Pacific
6.4.1 Introduction
6.4.2 China
6.4.3 India
6.4.4 Japan
6.4.5 Australia
6.4.6 South Korea
6.5 Latin America
6.5.1 Introduction
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Rest of Latin America
6.6 Middle East & Africa
6.6.1 Introduction
6.6.2 Middle-East
6.6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Minerva Biolabs GmbH
8.3 Charles River Laboratories International
8.4 Gibraltar Laboratories
8.5 Sartorius AG
8.6 Lonza Group Ltd.
8.7 Merck KGaA
8.8 Roche Diagnostics
8.9 SGS S.A.
8.10 American Type Culture Collection
8.11 InvivoGen
8.12 PromoCell GmbH
8.13 Biological Industries Israel Beit Haemek Ltd.
8.14 WuXi AppTec
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
FAQ's
As per our research report, the global mycoplasma testing market is projected to grow USD 1210.43 Million by 2027.
Based on the product, the kits & reagents segment accounted for the largest share of the global mycoplasma testing market in 2021.
Based on the technique, the PCR segment is predicted to be growing at the fastest CAGR from 2022 to 2027 in the global mycoplasma testing market.
Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Lonza Group Ltd., Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, PromoCell GmbH, WuXi AppTec are playing a key role in the mycoplasma testing market.
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
